Using Artificial Intelligence Applications in Neurology to the Field: Kathryn A. Davis, MD, MSc
April 22nd 2023The associate professor of neurology and director of the Penn Epilepsy Center at the University of Pennsylvania talked about the potential of using artificial intelligence in the field of neurology as part of an upcoming session at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]
Targeting Blood Vessels to Improve Treatment for Alzheimer Disease: Costantino Iadecola, MD
April 22nd 2023The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about the importance of vascular health in preventing cognitive impairment as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]
Expanding KP1077’s Clinical Program to Address Narcolepsy and Other Conditions: Christal Mickle
April 21st 2023The cofounder and chief product development officer of Zevra Therapeutics talked about the phase 1 clinical trial of KP1077 for narcolepsy and potentially using it to treat other conditions. [WATCH TIME: 5 minutes]
Advances in Neurology, Contributions to Brain Health: Costantino Iadecola, MD
April 20th 2023The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about brain health in relation to vascular health ahead of the 2023 AAN annual meeting. [WATCH TIME: 3 minutes]
Significance of New MOGAD Diagnosis Criteria, Inclusion of MOG-IgG: Anastasia Vishnevetsky, MD
April 19th 2023An immunology fellow at Brigham and Women’s Hospital provided perspective on the positive impacts a new diagnostic criterion for MOGAD brings to the clinical community. [WATCH TIME: 4 minutes]
Analyzing Specific Pathways in Cells to Prevent Relapse in NMOSD: Shuhei Nishiyama, MD, PhD
April 19th 2023The research fellow at the Neuroimmunology Clinic and Research Laboratory, Massachusetts General Hospital and Harvard Medical School, talked about his research of cell function in NMOSD to be presented at the upcoming AAN annual meeting. [WATCH TIME: 6 minutes]
Treatment of Dyskinesia in Patients with Parkinson’s Disease
Drs Rajesh Pahwa, Daniels Kremens and Fernando Pagan provide an overview of current treatment options for treatment of dyskinesia in patients with Parkinson’s Disease.
Challenges in Balancing Treatment of OFF Episodes and Dyskinesia in Parkinson Disease
The expert panel highlights challenges in treatment of OFF episodes and dyskinesia together and long-term consequences of delaying treatment for dyskinesia in patients with Parkinson disease.
Rehab Process and Need for Improved Guidelines of Basilar Artery Occlusions: Russell Cerejo, MD
April 18th 2023The vascular neurologist at Allegheny Health Network provided insight on the need to create consensus guidelines that further explain the treatment, management, and rehab of basilar artery occlusions. [WATCH TIME: 3 minutes]
Specific Considerations for Monoclonal Antibody Treatment in NMOSD: Shuhei Nishiyama, MD, PhD
April 17th 2023The research fellow at the Neuroimmunology Clinic and Research Laboratory, Massachusetts General Hospital and Harvard Medical School, talked about having safer and more specific treatments for NMOSD that are antigen-specific. [WATCH TIME: 4 minutes]
Evolution of High Intensity Focused Ultrasound to Treat Essential Tremor: Justin Sporrer, MD
April 14th 2023The director of functional neurosurgery at Baptist Health provided perspective on the advances of high intensity focused ultrasound as the institution nears 100 patients treated. [WATCH TIME: 4 minutes]
Clinical Application of Induced Pluripotent Stem Cells in Muscular Dystrophy: Rita Perlingeiro, PhD
April 13th 2023The Lillehei professor in stem cell and regenerative cardiovascular medicine at the University of Minnesota talked about the potential of investigating inducted pluripotent stem cells in neuromuscular diseases at MDA’s 2023 conference. [WATCH TIME: 5 minutes]
Clinical Trial Data for Efgartigimod in the Treatment of Myasthenia Gravis
April 13th 2023A. Gordon Smith, MD, FAAN, discusses the findings and implications of phase 3 ADAPT trial and open-label extension study evaluating the use of efgartigimod in the treatment of patients with myasthenia gravis.